2011, pp
Retatrutide is an investigational triple hormone agonist (GLP-1, GIP, glucagon) showing promising early results for obesity and type 2 diabetes, while tirzepatide is an FDA-approved dual agonist (GLP-1, GIP) available for use today
If you are exploring peptide therapy for sleep, recovery, body composition, or anti-aging goals, sermorelin and CJC-1295 are two of the most frequently discussed growth hormone-releasing peptides
Retatrutide is an investigational GLP-1, GIP, and glucagon triple receptor agonist currently in Phase 3 trials
Certificate of Analysis (COA) Each batch of CJC-1295 DAC is verified through HPLC and mass spectrometry analyses
Synergy with Hyaluronic Acid (HA): When co-administered with HA, AOD 9604 demonstrated superior efficacy in reducing lameness and structural damage compared to either agent alone